These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 28477403)

  • 21. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.
    Zhang D; Li L; Jiang H; Li Q; Wang-Gillam A; Yu J; Head R; Liu J; Ruzinova MB; Lim KH
    Cancer Res; 2018 Apr; 78(7):1700-1712. PubMed ID: 29363544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
    Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
    Duan W; Chen K; Jiang Z; Chen X; Sun L; Li J; Lei J; Xu Q; Ma J; Li X; Han L; Wang Z; Wu Z; Wang F; Wu E; Ma Q; Ma Z
    Cancer Lett; 2017 Jan; 385():225-233. PubMed ID: 27773749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
    Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.
    Shah A; Jahan R; Kisling SG; Atri P; Natarajan G; Nallasamy P; Cox JL; Macha MA; Sheikh IA; Ponnusamy MP; Kumar S; Batra SK
    Cancer Lett; 2024 Aug; 598():217097. PubMed ID: 38964729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
    Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
    Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition.
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA;
    Cancer Res; 2021 Jul; 81(13):3461-3479. PubMed ID: 33980655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
    Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
    Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
    Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
    Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 36. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool.
    Delpu Y; Lulka H; Sicard F; Saint-Laurent N; Lopez F; Hanoun N; Buscail L; Cordelier P; Torrisani J
    PLoS One; 2013; 8(1):e55513. PubMed ID: 23383211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
    Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
    Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer.
    Neumann CCM; von Hörschelmann E; Reutzel-Selke A; Seidel E; Sauer IM; Pratschke J; Bahra M; Schmuck RB
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):461-472. PubMed ID: 30243879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.